CPP
HTGM

Crow Point Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Crow Point Partners’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-260
Closed -$29K – 152
2019
Q3 		$29K Sell
260
-53
-17% -$10.7K ﹤0.01% 125
2019
Q2 		$93K Sell
313
-150
-32% -$62.6K 0.01% 120
2019
Q1 		$208K Buy
463
+99
+27% +$43.3K 0.04% 110
2018
Q4 		$164K Sell
364
-7
-2% -$4.34K 0.03% 112
2018
Q3 		$337K Buy
371
+227
+158% +$150K 0.06% 104
2018
Q2 		$84K Buy
144
+61
+73% +$39.8K 0.02% 118
2018
Q1 		$54K Buy
+83
New +$62.3K 0.01% 194

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HWM
HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return